Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
出版年份 2020 全文链接
标题
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e000772
出版商
BMJ
发表日期
2020-07-21
DOI
10.1136/jitc-2020-000772
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells
- (2019) Sema Kurtulus et al. IMMUNITY
- A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of non-immunogenic tumors to allow T cell-mediated anticancer activity
- (2019) Hayley S. Ma et al. Cancer Immunology Research
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
- (2019) Brian C. Miller et al. NATURE IMMUNOLOGY
- Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer
- (2019) Brett J. Hos et al. OncoImmunology
- European cancer mortality predictions for the year 2018 with focus on colorectal cancer
- (2018) M Malvezzi et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer
- (2018) Valeria Quaranta et al. CANCER RESEARCH
- Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
- (2018) Thomas Duhen et al. Nature Communications
- NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
- (2018) Nadine van Montfoort et al. CELL
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma
- (2018) Hanjie Li et al. CELL
- Metabolic and Epigenetic Coordination of T Cell and Macrophage Immunity
- (2017) Anthony T. Phan et al. IMMUNITY
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
- (2017) Vinod P. Balachandran et al. NATURE
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- IFN and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma
- (2016) K. B. Long et al. Cancer Discovery
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages
- (2015) Gregory L. Beatty et al. GASTROENTEROLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study
- (2015) Ippei Matsumoto et al. PANCREATOLOGY
- T cell metabolic fitness in antitumor immunity
- (2015) Peter J. Siska et al. TRENDS IN IMMUNOLOGY
- Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma
- (2015) Alessandro Paniccia et al. JAMA Surgery
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- The Glucose Transporter Glut1 Is Selectively Essential for CD4 T Cell Activation and Effector Function
- (2014) Andrew N. Macintyre et al. Cell Metabolism
- Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity
- (2014) Ingunn M Stromnes et al. GUT
- CD40 immunotherapy for pancreatic cancer
- (2013) Robert H. Vonderheide et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Network Analysis Reveals Centrally Connected Genes and Pathways Involved in CD8+ T Cell Exhaustion versus Memory
- (2012) Travis A. Doering et al. IMMUNITY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity?
- (2010) Vegard Tjomsland et al. BMC CANCER
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Antigens for cancer immunotherapy
- (2008) Michelle A. Neller et al. SEMINARS IN IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now